Ion Exchange provides water treatment solutions across three segments: engineering (EPC projects), chemicals (resins and membranes), and consumer products. In Q4 FY26, engineering revenue was INR 5,539 million with a 3.9% EBIT margin, while chemicals delivered INR 2,297 million at a 14.5% EBIT margin, reflecting the higher quality of the chemical business. The consumer division grew 34% YoY to INR 1,047 million but still lost INR 46 million. Consolidated FY26 EBITDA margin was 7.21% and PAT margin 4.91%, weighed down by Roha plant costs and one-off export deferrals. The company holds a leading position in India's industrial water treatment, with an order book of INR 26,433 million as of 31 Mar 2026.
The chemical segment's economics persist due to certification and qualification barriers. The Roha plant, with 42,600 cubic meters capacity, received WQA certification after Q4 FY26, unlocking the US drinking water market. Customer qualification cycles for resins and membranes are lengthy, and the MANN+HUMMEL technology transfer for UF PVDF membranes and MBR adds proprietary know-how. The company is one of the few non-Chinese manufacturers with a full RO, UF, and NF range, giving it pricing power. Engineering, in contrast, is a competitive project business with high single-digit margins, but the company's 40-year track record in ultra-pure water for semiconductors and selective bidding provides some insulation. The order book, with inflow 40% higher than the prior year, ensures revenue visibility.
The inflection is the Roha ramp and international expansion. Management targets 25% capacity utilization in FY27, the first full year of operation, with full capacity in four years. By mid-2028, utilization should reach 40-50%, spreading fixed costs and lifting chemical margins. The MANN+HUMMEL partnership will commercialize new membranes, and the Dammam plant in Saudi Arabia has started production. The Oman DBOOT contract (OMR 73.46 million) is progressing, with USD 40 million CAPEX over two years, and the Malawi project (USD 18.1 million) adds international revenue. Consumer products are targeted to break even in FY27, and the legacy Sri Lanka project closes by Q2 FY27. Engineering margins should recover as legacy projects wind down and the order book executes.
Management's walk-talk is mixed but improving. In Feb 2026, they admitted Roha was only 40-45% commissioned, a slippage from earlier guidance; by Jun 2026, the plant was fully commissioned with WQA certification, but revenue contribution is deferred to FY27. They have delivered on order inflow (40% higher) and secured new contracts like the two solar projects (INR 2,050 million). They have been transparent about the West Asia crisis deferring ~INR 60 crore of export shipments. Capital allocation is disciplined: gross debt is ~INR 384 crores, maintenance CAPEX for FY27 is INR 30-40 crores, and the Oman CAPEX will be funded by debt and equity without dilution. They have not provided quantitative FY27 guidance, citing geopolitical uncertainty, but expect to give clarity in H2 FY27.
The earnings path is visible: FY27 should see Roha at 25% utilization, consumer breakeven, and engineering margins improving as legacy projects close. By FY28, Roha utilization could reach 40-50%, and international projects will contribute. The key watchpoint is Roha's utilization ramp; if it stays below 25% or certifications slip, margin recovery will be delayed. Also, UP Jal Jeevan receivables (30% of scope pending) and West Asia logistics remain risks. The tension between Q4's 2.31% EBITDA margin and management's confidence is resolved by the fact that the low margin was driven by one-off export deferrals and Roha capitalization, not structural erosion. As chemical price hikes take effect and Roha's fixed costs are absorbed, EBITDA margin should return to double digits by FY28.
companyname: Ion Exchange (India) Limited ticker: IONEXCHANG sector: Water and Environment Management / Water Treatment Solutions Ion Exchange (India) Limited is a water and environment management company built around three businesses that share one technical core: treating, purifying, and recycling water. The Engineering segment (63% of FY25 turnover) designs and builds water and wastewater treatment plants. The Chemical segment (26%) manufactures the ion exchange resins and specialty chemical...
Read the full report →capex, margin expansion, regulatory approval, geographic expansion
FY27 Roha plant capacity utilization guided at 25% driven by full commissioning and certification
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Ion Exchange (India) Limited and 4,900+ companies.
5-day free pass. No card required.